COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Interstitial Cystitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00056251
Recruitment Status : Completed
First Posted : March 10, 2003
Last Update Posted : June 24, 2005
Information provided by:
ICOS Corporation

Tracking Information
First Submitted Date  ICMJE March 7, 2003
First Posted Date  ICMJE March 10, 2003
Last Update Posted Date June 24, 2005
Study Start Date  ICMJE January 2003
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE Not Provided
Original Primary Outcome Measures  ICMJE Not Provided
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Interstitial Cystitis
Official Title  ICMJE A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of RTX Topical Solution in Patients With Interstitial Cystitis
Brief Summary Patients with interstitial cystitis who meet eligibility requirements will be randomized to one of four treatment arms (3 RTX, Placebo). Study drug is administered as a single instillation within the urinary bladder. Study duration is 12 weeks.
Detailed Description


Topical resiniferatoxin (RTX) administrated to the bladder may be effective in decreasing the symptoms associated with interstitial cystitis through its action on pain sensing neurons.


Randomized, double-blind, placebo-controlled, Phase 2 trial to determine the safety and efficacy of RTX in patients with interstitial cystitis.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Interstitial Cystitis
Intervention  ICMJE Procedure: H&P; ECG; Blood tests; voiding diary; Cystoscopy
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: June¬†23,¬†2005)
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE August 2003
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • ≥ 18 years of age.
  • Have IC that meets disease diagnostic criteria as defined by a history of the following:
  • Cystoscopy/hydrodistension with a diagnosis of IC confirmed by findings of Hunner's ulcer or glomerulation
  • Symptoms of bladder pain and urinary urgency for at least 6 months
  • Urinary frequency while awake at least 8 times a day while awake
  • Nocturia at least twice a night
  • Symptoms not significantly relieved by antimicrobial agents, anticholinergic drugs, or antispasmodics
  • Have IC that in the judgment of the investigator has been stable in the previous 30 days
  • Have IC-related pain despite current therapy, defined as a score of 4 or greater [(on a scale from 0 (none) to 9 (severe)] on average over the past month and confirmed by the voiding diary collected at Visit 2
  • Have at least one voided volume ≥ 75 cc in a 24 hour period, confirmed by the voiding diary collected at Visit 2
  • Patients of childbearing potential must agree to use an acceptable form of contraception (oral contraceptives, intrauterine device or double barrier methods) from Visit 1 through Visit 6
  • Provide signed informed consent

Exclusion Criteria:

  • Currently pregnant or breastfeeding
  • Presence of ulcers on the pre-treatment cystoscopy
  • Intravesical therapy or bladder hydrodistention within the previous 60 days
  • Initiation of pentosan polysulfate sodium (Elmiron®) within the previous 16 weeks
  • Use of fentanyl patches, morphine sulfate, methadone or B&O supprettes within the previous 30 days.
  • Previous augmentation cystoplasty, cystectomy or cystolysis, neurectomy (i.e., hypogastric nerve plexus ablation) or implanted peripheral nerve stimulator which has affected bladder function
  • History of ureteral reflux. Patients with a history of childhood urinary tract infections, recurrent urinary tract infections as an adult (defined as >3 culture documented episodes within the previous 12 months), or pyelonephritis at any time must have a cystourethogram to rule out ureteral reflux.
  • Evidence of renal impairment (creatinine > 2 times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > 3 times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases
  • Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound the interpretation of the study results
  • Treatment with a drug or medical device that has not received regulatory approval within the previous 30 days
  • Investigators, study staff and their immediate families. Immediate family is defined as current spouse, parent, natural or legally adopted child (including a stepchild living in the investigator's household), grandparent, or grandchild.
  • Previously completed or withdrawn from this study
  • Urinary tract or prostatic infection within the past 3 months before study entry
  • Active genital herpes or vaginitis
  • Urethral diverticulum
  • Uterine, cervical, vaginal, or urethral cancer within the past 5 years before study entry
  • History of cyclophosphamide or chemical cystitis, urinary tuberculosis or radiation cystitis
  • History of bladder tumors (benign or malignant)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00056251
Other Study ID Numbers  ICMJE JIC01
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE ICOS Corporation
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Lyn Frumkin, M.D., Ph.D. ICOS Corporation, (425) 415-5571,
PRS Account ICOS Corporation
Verification Date January 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP